Welcome to our dedicated page for Acumen Pharmaceuticals SEC filings (Ticker: ABOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Acumen Pharmaceuticals, Inc. filings document a clinical-stage biopharmaceutical issuer focused on Alzheimer’s disease programs targeting toxic soluble amyloid beta oligomers. Its Form 8-K reports include operating and financial results, business highlights, Regulation FD presentation updates, clinical and nonclinical program disclosures, and material agreements related to Enhanced Brain Delivery development.
Proxy materials describe annual meeting voting matters, board elections, auditor ratification, and equity incentive plan approvals. The filing record also discloses ABOS common stock registered on the Nasdaq Global Select Market, emerging growth company status, governance changes, capital-structure matters, and clinical and regulatory disclosure categories tied to drug development.
Acumen Pharmaceuticals, Inc. is a clinical-stage biotech focused on Alzheimer’s disease, advancing its anti-amyloid-beta oligomer antibody sabirnetug in the Phase 2 ALTITUDE-AD trial, with top-line results planned for late 2026. The company also nominated two Enhanced Brain Delivery™ candidates, ACU301 and ACU401, under its JCR collaboration and exercised an option in June 2026, triggering a $9.25 million in‑process R&D payment.
For the six months ended June 30, 2026, Acumen reported a net loss of $53.5 million, improving from $69.7 million in 2025, as research and development expenses fell to $44.3 million from $62.4 million primarily due to lower manufacturing and CRO costs on ALTITUDE-AD. General and administrative expenses were stable at $9.4 million. Cash, cash equivalents and marketable securities totaled $110.2 million as of June 30, 2026, helped by a March 2026 private placement raising about $35.7 million gross.
The company carries an accumulated deficit of $499.9 million and continues to incur operating losses. Management states that current cash resources are expected to fund operations into early 2027 but may not cover at least 12 months beyond the financial statement issuance date, leading to a disclosed substantial doubt about its ability to continue as a going concern.
Acumen Pharmaceuticals, Inc. reported second quarter 2026 results and updated progress on its Alzheimer’s disease pipeline. For the quarter ended June 30, 2026, the company recorded a net loss of $32.7 million, improved from $41.0 million a year earlier, as research and development expenses declined to $27.8 million from $37.1 million, mainly from lower manufacturing, materials and CRO costs tied to the ALTITUDE-AD trial. General and administrative expenses were stable at $4.7 million.
Cash, cash equivalents and marketable securities totaled $110.2 million as of June 30, 2026, down from $128.4 million at March 31, 2026, and are expected to fund current clinical and operational activities into early 2027. The balance sheet showed total assets of $116.0 million, total liabilities of $58.7 million and stockholders’ equity of $57.3 million, with short-term debt of $19.7 million and long-term debt of $11.9 million. The company raised $35.4 million net from a private placement in the first half of 2026.
Operationally, Acumen highlighted its Phase 2 ALTITUDE-AD trial of sabirnetug (ACU193) in 542 participants with early Alzheimer’s disease, with topline results expected in late 2026, and continued development of its Enhanced Brain Delivery™ (EBD™) program, targeting an IND filing for a lead EBD candidate in mid-2027.
Acumen Pharmaceuticals director Derrell Porter reported a series of option exercises and matching share sales in Common Stock. On June 15–17, 2026, he exercised options for a total of 19,500 shares at $1.07 per share and sold 32,300 shares in open-market transactions at weighted average prices around $2.32 per share, with individual trades ranging from $2.305 to $2.345. Following these transactions, Porter directly holds 35,500 shares of Acumen Pharmaceuticals Common Stock. The options exercised had vested in full on the date of the 2026 annual stockholder meeting.
ABOS files a Rule 144 notice for the sale of 13,040 shares. The filing lists the method as a Stock Option Exercise dated 06/17/2026 with cash proceeds. It also reports prior dispositions of 12,800 shares on 06/16/2026 for $29,767.68 and 6,460 shares on 06/15/2026 for $15,148.70.
ABOS reported a Form 144 notice for insider sales. The filing lists 12,800 shares of restricted common stock to be sold and shows 6,460 shares sold on 06/15/2026 for $15,148.70. The broker listed is Morgan Stanley Smith Barney LLC and the filing references NASDAQ.
Acumen Pharmaceuticals has nominated two Enhanced Brain Delivery (EBD) development candidates, ACU301 and ACU401, for Alzheimer’s disease under its collaboration with JCR Pharmaceuticals and has exercised its option to license and develop them. The candidates combine Acumen’s amyloid-beta oligomer–selective antibodies with JCR’s J-Brain Cargo blood-brain barrier–penetrating technology.
Both candidates showed strongly enhanced brain penetration in non-human primates, with antibody levels 14–40x higher than native antibodies at 24 hours, low anemia risk and no observed adverse events across tested species. They also demonstrated favorable stability and plasma pharmacokinetics after subcutaneous dosing. Acumen is conducting Investigational New Drug–enabling activities to support a planned IND submission in mid-2027 while continuing its Phase 2 ALTITUDE-AD trial of sabirnetug (ACU193) in early Alzheimer’s disease.
Acumen Pharmaceuticals director Nathan B. Fountain reported an open-market sale of 6,400 shares of Common Stock. The shares were sold on June 9, 2026 at a weighted average price of about $2.23 per share. After this transaction, he directly holds 48,150 shares of Acumen common stock.
Acumen Pharmaceuticals reported an equity compensation grant linked to director Dr. Laura Stoppel, as reflected on this Form 4 by RA Capital entities and related reporting persons. Dr. Stoppel received a restricted stock unit award covering 35,500 shares of common stock and a stock option for 53,250 shares with a $2.29 exercise price.
The RSUs and option will each vest in full on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting, assuming Dr. Stoppel continues in service through that date. Under her arrangement with RA Capital Management, L.P., she holds these awards for the benefit of RA Capital Healthcare Fund, RA Capital Nexus Fund II and a separately managed account, and must deliver any net stock or cash received to the adviser to offset advisory fees. The reporting persons disclaim beneficial ownership of these awards and the underlying common stock beyond any pecuniary interest.